|
CA2604238C
(en)
|
2005-04-15 |
2015-07-07 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
AU2008284015B2
(en)
*
|
2007-08-03 |
2014-05-15 |
Musc Foundation For Research Development |
Human monoclonal antibodies and methods for producing the same
|
|
CN101854946B
(zh)
*
|
2007-11-08 |
2013-07-03 |
尼尔詹尼克斯肿瘤研究公司 |
结肠癌和胰腺癌的重组单克隆抗体和相应抗原
|
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
US9050317B2
(en)
*
|
2008-10-31 |
2015-06-09 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US20100111835A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8409376B2
(en)
|
2008-10-31 |
2013-04-02 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US9060934B2
(en)
*
|
2008-10-31 |
2015-06-23 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US8731840B2
(en)
|
2008-10-31 |
2014-05-20 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8551506B2
(en)
*
|
2008-10-31 |
2013-10-08 |
The Invention Science Fund I, Llc |
Compositions and methods for administering compartmentalized frozen particles
|
|
US9040087B2
(en)
|
2008-10-31 |
2015-05-26 |
The Invention Science Fund I, Llc |
Frozen compositions and methods for piercing a substrate
|
|
US8793075B2
(en)
*
|
2008-10-31 |
2014-07-29 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US9060926B2
(en)
*
|
2008-10-31 |
2015-06-23 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US9050070B2
(en)
*
|
2008-10-31 |
2015-06-09 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US8603495B2
(en)
*
|
2008-10-31 |
2013-12-10 |
The Invention Science Fund I, Llc |
Compositions and methods for biological remodeling with frozen particle compositions
|
|
US8603496B2
(en)
*
|
2008-10-31 |
2013-12-10 |
The Invention Science Fund I, Llc |
Compositions and methods for biological remodeling with frozen particle compositions
|
|
US8551505B2
(en)
*
|
2008-10-31 |
2013-10-08 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US9050251B2
(en)
*
|
2008-10-31 |
2015-06-09 |
The Invention Science Fund I, Llc |
Compositions and methods for delivery of frozen particle adhesives
|
|
US20100111841A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US8849441B2
(en)
|
2008-10-31 |
2014-09-30 |
The Invention Science Fund I, Llc |
Systems, devices, and methods for making or administering frozen particles
|
|
US20100111836A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US8721583B2
(en)
*
|
2008-10-31 |
2014-05-13 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US8762067B2
(en)
|
2008-10-31 |
2014-06-24 |
The Invention Science Fund I, Llc |
Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
|
|
US8725420B2
(en)
*
|
2008-10-31 |
2014-05-13 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US8545855B2
(en)
*
|
2008-10-31 |
2013-10-01 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US9072799B2
(en)
|
2008-10-31 |
2015-07-07 |
The Invention Science Fund I, Llc |
Compositions and methods for surface abrasion with frozen particles
|
|
US9060931B2
(en)
*
|
2008-10-31 |
2015-06-23 |
The Invention Science Fund I, Llc |
Compositions and methods for delivery of frozen particle adhesives
|
|
US8788211B2
(en)
*
|
2008-10-31 |
2014-07-22 |
The Invention Science Fund I, Llc |
Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
|
|
US8731841B2
(en)
|
2008-10-31 |
2014-05-20 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US20100111831A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for surface abrasion with frozen particles
|
|
US9072688B2
(en)
|
2008-10-31 |
2015-07-07 |
The Invention Science Fund I, Llc |
Compositions and methods for therapeutic delivery with frozen particles
|
|
US20100111857A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Boyden Edward S |
Compositions and methods for surface abrasion with frozen particles
|
|
US8545857B2
(en)
*
|
2008-10-31 |
2013-10-01 |
The Invention Science Fund I, Llc |
Compositions and methods for administering compartmentalized frozen particles
|
|
US20100111834A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Compositions and methods for therapeutic delivery with frozen particles
|
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
|
EP2545079A2
(en)
|
2010-03-11 |
2013-01-16 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
|
US20130189268A1
(en)
*
|
2010-06-22 |
2013-07-25 |
Precision Biologics, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
|
US9068014B2
(en)
|
2010-09-23 |
2015-06-30 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
|
AR088693A1
(es)
|
2011-11-11 |
2014-06-25 |
Rinat Neuroscience Corp |
Anticuerpos especificos para trop-2 y sus usos
|
|
HK1204328A1
(en)
|
2011-12-22 |
2015-11-13 |
瑞纳神经科学公司 |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
|
WO2014072876A1
(en)
|
2012-11-09 |
2014-05-15 |
Pfizer Inc. |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
|
JP6576831B2
(ja)
*
|
2012-12-28 |
2019-09-18 |
プレシジョン・バイオロジクス・インコーポレイテッド |
結腸癌及び膵臓癌の診断ならびに治療のための、ヒト化モノクローナル抗体及び使用方法
|
|
WO2014181229A2
(en)
|
2013-05-07 |
2014-11-13 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
|
AR097102A1
(es)
|
2013-08-02 |
2016-02-17 |
Pfizer |
Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco
|
|
AU2014348676B2
(en)
|
2013-11-13 |
2020-06-18 |
Bristol-Myers Squibb Company |
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
HRP20210292T1
(hr)
|
2014-04-30 |
2021-04-16 |
Pfizer Inc. |
Anti-ptk7 protutijelo-lijek konjugati
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
|
PL3988117T3
(pl)
|
2015-04-13 |
2025-03-10 |
Pfizer Inc. |
Przeciwciała terapeutyczne i ich zastosowania
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
KR102876923B1
(ko)
|
2015-10-23 |
2025-10-28 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
|
EP3405490B1
(en)
|
2016-01-21 |
2021-10-20 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
|
HUE070615T2
(hu)
|
2016-10-17 |
2025-06-28 |
Pfizer |
Anti-EDB antitestek és antitest-gyógyszer konjugátumok
|
|
KR20190141655A
(ko)
*
|
2017-02-22 |
2019-12-24 |
알레타 바이오쎄라퓨틱스, 인크. |
종양 형질도입용 조성물 및 방법
|
|
PE20191487A1
(es)
|
2017-03-03 |
2019-10-18 |
Rinat Neuroscience Corp |
Anticuerpos anti-gitr y metodos de uso de los mismos
|
|
TWI843344B
(zh)
|
2017-06-02 |
2024-05-21 |
美商輝瑞大藥廠 |
對ｆｌｔ３具特異性之抗體及其用途
|
|
MY210421A
(en)
|
2018-01-26 |
2025-09-22 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
IL302626B2
(en)
|
2018-01-26 |
2025-12-01 |
Exelixis Inc |
Compounds for the treatment of kinase-dependent disorders
|
|
MA51679A
(fr)
|
2018-01-26 |
2020-12-02 |
Exelixis Inc |
Composés destinés au traitement de troubles dépendant de la kinase
|
|
PE20210708A1
(es)
|
2018-02-01 |
2021-04-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
IL276396B2
(en)
|
2018-02-01 |
2026-01-01 |
Pfizer |
Chimeric antigen receptors against CD70
|
|
CA3091181A1
(en)
|
2018-02-13 |
2019-08-22 |
Precision Biologics, Inc. |
Methods and compositions for targeting treg cells
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
PL3797121T3
(pl)
|
2018-05-23 |
2024-09-23 |
Pfizer Inc. |
Przeciwciała swoiste dla CD3 i ich zastosowania
|
|
EP3796983A2
(en)
|
2018-05-23 |
2021-03-31 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
|
PL3894012T3
(pl)
|
2018-12-13 |
2026-01-05 |
Exelixis, Inc. |
Postacie krystaliczne i postacie soli inhibitora kinazy
|
|
CN113710322A
(zh)
|
2019-01-25 |
2021-11-26 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
|
EP3927430A1
(en)
|
2019-02-18 |
2021-12-29 |
Pfizer Inc. |
Method of treatment of chronic low back pain
|
|
US20220202818A1
(en)
|
2019-04-18 |
2022-06-30 |
The Regents Of The University Of Michigan |
Combination with checkpoint inhibitors to treat cancer
|
|
GEAP202415849A
(en)
|
2019-06-03 |
2024-03-11 |
Exelixis Inc |
Crystalline salt forms of kinase inhibitor
|
|
AR119069A1
(es)
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
|
MX2022016590A
(es)
|
2020-06-26 |
2023-02-01 |
Pfizer |
Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.
|
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
WO2022040555A2
(en)
|
2020-08-21 |
2022-02-24 |
Exelixis, Inc. |
Method of treating cancer
|
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
|
WO2023122739A1
(en)
|
2021-12-22 |
2023-06-29 |
Exelixis, Inc. |
Crystalline forms and salt forms of a kinase inhibitor
|
|
AU2023228391A1
(en)
|
2022-03-03 |
2024-09-19 |
Pfizer Inc. |
Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
|
CA3256751A1
(en)
|
2022-05-26 |
2023-11-30 |
Pfizer Inc. |
Anti-TNFR2 antibodies and their methods of use
|
|
EP4532542A1
(en)
|
2022-05-31 |
2025-04-09 |
Pfizer Inc. |
Anti-bmp9 antibodies and methods of use thereof
|
|
CA3259654A1
(en)
|
2022-06-17 |
2023-12-21 |
Pfizer Inc. |
IL-12 VARIANTS, ANTI-PD1 ANTIBODIES, FUSING PROTEINS AND THEIR USES
|
|
PE20251076A1
(es)
|
2022-08-03 |
2025-04-10 |
Pfizer |
Anticuerpos anti-il27r y metodos de usos de estos
|
|
WO2024062420A1
(en)
|
2022-09-22 |
2024-03-28 |
Pfizer Inc. |
METHODS OF TREATMENT WITH IFNß ANTIBODIES
|
|
EP4651889A1
(en)
|
2023-01-18 |
2025-11-26 |
Pfizer Inc. |
Vaccines against respiratory diseases
|
|
WO2024218650A1
(en)
|
2023-04-19 |
2024-10-24 |
Pfizer Inc. |
Lilrb1 and lilrb2 antibodies and methods of use thereof
|
|
WO2024239006A1
(en)
|
2023-05-17 |
2024-11-21 |
Genentech, Inc. |
Anti-tl1a antibody therapeutic methods
|
|
WO2025007862A1
(zh)
|
2023-07-03 |
2025-01-09 |
施慧达药业集团(吉林)有限公司 |
蛋白质异二聚体的治疗用途
|
|
TW202535956A
(zh)
|
2023-11-10 |
2025-09-16 |
美商輝瑞大藥廠 |
抗ＭＩＧＩＳ－α抗體及其使用方法
|
|
US20250163168A1
(en)
|
2023-11-17 |
2025-05-22 |
Pfizer Inc. |
Novel antibodies and antibody conjugates for the treatment of metabolic disorders
|
|
WO2025257715A1
(en)
|
2024-06-12 |
2025-12-18 |
Seagen Inc. |
Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof
|